Michigan MMP Provider Fact Sheet

Based on interviews conducted in the 2009 MMP cycle

What is the Medical Monitoring Project (MMP)?

- MMP is an ongoing population-based surveillance system to assess clinical outcomes and behaviors of HIV-infected persons receiving care in the U.S.
- It is currently conducted in 17 states and 6 cities by local and state public health departments in collaboration with the Centers for Disease Control and Prevention (CDC).

Data Collected from the State of Michigan

- The following provides a few examples of the kind of self-reported data collected in the patient interview.

Patient Demographic Information*

Race/Ethnicity	Male† (n=117) No. (%)	Female (n=44) No. (%)	Total (n=161) No. (%)
White, non-Hispanic	40 (34%)	10 (23%)	50 (31%)
Black, non-Hispanic	71 (61%)	32 (73%)	103(64%)
Hispanic	3 (3%)	1 (2%)	4 (2%)
Other	3 (3%)	1 (2%)	4 (2%)

"Other" racial group includes Asian and multiracial
†2 participants refused to answer and were excluded

Age at the Time of Interview	Male (n=119) No. (%)	Female (n=44) No. (%)	Total (n=163) No. (%)
18-24	2 (2%)	1 (2%)	3 (2%)
25-34	6 (5%)	3 (7%)	9 (6%)
35-44	32 (27%)	14 (32%)	46 (28%)
45-54	55 (46%)	16 (36%)	71 (44%)
55+	24 (20%)	10 (23%)	34 (21%)

**1 participant identified as transgender and so was excluded from patient demographic information based on small number*

Health Coverage

Any Health Coverage in the Past 12 Months (N=164)*



**Self-reported health coverage in response to the question "During the past 12 months, have you had any kind of health insurance or health coverage? This includes Medicaid and Medicare"*
† Self-reported gap in health coverage in response to the question "During the past 12 months, was there a time that you didn't have any health insurance or health coverage?"

In the 12 months prior to interview:

- 13% (n=22) had an HIV related ER visit
- 10% (n=17) had an HIV related hospitalization

Clinical Outcomes

From the 2009 MMP self-reported interview data, 97% of 159 participants had at least 1 CD4 count and 95% of 156 participants had at least 1 viral load test in the 12 months prior to interview (median=3, range 1-12; excludes participants who both don't know if they ever had a CD4 count or viral load test and those who do not know how many CD4 counts or viral load tests they had in the 12 months prior to interview). The median number of CD4 counts and viral load tests meets the current recommended treatment guidelines.

Self-reported Lowest Ever CD4 Count (N=162)*



Self-reported Highest Viral Load Test Ever (N=161)*



**Excluding participants who don't know if they ever had a CD4 count or viral load test*

Time between HIV Diagnosis and Entry into Care

- Most participants received an HIV diagnosis >5 years prior to the interview. Among participants interviewed within 5 years of their self-reported HIV diagnosis date (21%, n=34):
  - 82% (n=28) entered HIV care in <=3 months following diagnosis

- 9% (n=3) entered HIV care between 3 and 12 months following diagnosis
- 9% (n=3) did not recall the month and year they first entered care for HIV

Antiretroviral Therapy

- 17% (n=24) of those currently on ARV meds have missed taking medication in the past week

Currently on Antiretroviral Therapy at Time of Interview	Male (n=119)	Female (n=44)	Total (n=163)
No	16 (13%)	5 (11%)	21 (13%)
Yes	103 (87%)	39 (89%)	142 (87%)

**1 participant identified as transgender (n=1) and was excluded based on small number*

- Of those not currently on antiretroviral (ARV) meds, 52% (n=11) have never taken ARV meds
  - Main reason: Doctor advised to delay treatment (64%, n=7)
- The remaining 48% (n=10) have formerly, but are not currently taking ARV meds
  - Main reason: Doctor advised to delay or stop treatment (40%, n=4)

Sexual Behavior

In the 12 months prior to interview:

- 34% (n=41) of males had no sexual partners
- 48% (n=21) of females had no male sexual partners
- 54% (n=45) had alcohol before or during sex

Number of Sexual Partners in the Past 12 Months*†	MSM (n= 51)**	MSW (n=27)**	WSM (n=23)
One	26 (51%)	21 (78%)	22 (96%)
Two or more	25 (49%)	6 (22%)	1 (4%)
No. of partners (range)	1-30	1-4	1-4

Reported Unprotected Vaginal or Anal Sex with at Least 1 Partner in the Past 12 Months*	MSM (n=40)	MSW (n=24)	WSM (n=22)
No	19 (48%)	15 (63%)	14 (64%)
Yes	21 (53%)	9 (38%)	8 (36%)

**Men who have sex with men (MSM), men who have sex with women (MSW), women who have sex with men (WSM); note that these MSM and MSW are not mutually exclusive categories*
†Includes oral, anal, and vaginal sex
***1 missing-refused to answer*

Substance Use

Non-Injection Drug Use in the Past 12 Months*	Male† (n=118)	Female (n=44)	Total (n=162)
Yes	44 (37%)	12 (27%)	56 (35%)
No	74 (63%)	32 (73%)	106 (65%)

**Excluding alcohol and excluding transgender participant (n=1)*
†1 missing- don't know

- Of those that used non-injection drugs in the last 12 months, the most commonly used drugs were marijuana (96%, n=54), cocaine (18%, n=10), and crack (14%, n=8)
- 1% (n=2) injected drugs in the past 12 months
- 75% (n=123) used alcohol in the past 12 months

Services Used and Services Needed

- The most commonly used services in the 12 months prior to interview were:
  - HIV case management (n=83): 51%
  - Dental services (n=82): 50%
  - Public benefits including SSI and SSDI (n=61): 37%
  - HIV prevention education (n=61): 37%

Top 10 Services Needed but Didn't Receive
During the 12 months prior to interview (N=164)



Why should I participate in MMP?

- The answers provided by MMP may be used by prevention planning groups, clinicians, Ryan White consortia, and policy leaders to help advocate for additional resources.
- MMP presents a unique opportunity to contribute to knowledge about HIV care in the U.S.
- MMP's true success depends upon the participation of HIV health care providers like you.
- The sample, including your site, was carefully selected to ensure that patients selected for MMP are truly representative of patients in care in Michigan and another site cannot be selected as a replacement.
- The higher the participation rate of providers and patients, the more representative and valid the results

Questions about MMP?

- If you are interested in learning more about MMP or have any questions, please contact:

Meosia Lee-Turner
Project Coordinator (PC) (313) 876-0072

We would like to thank our participating MMP providers and participants for their time and support

Note: Percentages in tables may not add up to 100% due to rounding